Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Expression of Pituitary Tumor Transforming Gene 1 is an Independent Factor of Poor Prognosis in Localized or Locally Advanced Prostate Cancer Cases Receiving Hormone Therapy

  • Cao, Xi-Liang (Department of Urology, Chinese People's Liberation Army General Hospital) ;
  • Gao, Jiang-Ping (Department of Urology, Chinese People's Liberation Army General Hospital) ;
  • Wang, Wei (Department of Urology, Chinese People's Liberation Army General Hospital) ;
  • Xu, Yong (Department of Urology, Chinese People's Liberation Army General Hospital) ;
  • Shi, Huai-Yin (Department of Pathology, Chinese People's Liberation Army General Hospital) ;
  • Zhang, Xu (Department of Urology, Chinese People's Liberation Army General Hospital)
  • Published : 2012.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

We investigated the prognostic value of pituitary tumor transforming gene 1 (PTTG1) expression according to clinicopathological features among localized or locally advanced prostate cancer cases receiving hormone therapy. A retrospective study involved 64 patients receiving combined androgen blockade treatment was performed. PTTG1 expression was determined by immunohistochemical staining using initial needle biopsy specimens for diagnosis. Associations of PTTG1 with various clinicopathological features and disease-free survival were examined via uni- and multivariate analyses. No association between PTTG1 expression and clinical T stage, Gleason score, pretreatment PSA levels, risk groups was found (p =0.682, 0.184, 0.487, 0.571, respectively). Univariate analysis revealed that increased PTTG1 expression, T3 stage and high risk group were associated with increased risk of disease progression (p =0.000, 0.042, and 0.001), and high PSA level had a tendency to predict disease progression (p =0.056). Cox hazard ratio analysis showed that PTTG1 low expression (p =0.002), PTTG1 high expression (p =0.000) and high risk group (p =0.0147) were significantly related to decreased disease-free survival. In conclusion, PTTG1 expression determined by immunohistochemical staining in needle biopsy specimens for diagnosis is a negative prognostic factor for progression in localized or locally advanced prostate cancer receiving hormone therapy.

Keywords

References

  1. Abouassaly R, Paciorek A, Ryan CJ, Carroll PR, Klein EA (2009). Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE. Cancer, 115, 4470-6. https://doi.org/10.1002/cncr.24526
  2. Akaza H, Homma Y, Usami M, et al (2006). Efficacy of primary hormone therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU Int, 98, 573-9. https://doi.org/10.1111/j.1464-410X.2006.06349.x
  3. Akaza H, Usami M, Hinotsu S, et al (2004). Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Jpn J Cli Oncol, 34, 329-36. https://doi.org/10.1093/jjco/hyh061
  4. Bonkhoff H, Berges R (2009). The evolving role of oestrogens and their receptors in the development and progression of prostate cancer. Eur Urol, 55, 533-42. https://doi.org/10.1016/j.eururo.2008.10.035
  5. Celhay O, Yacoub M, Irani J, et al (2010). Expression of estrogen related proteins in hormone refractory prostate cancer: association with tumor progression. J Urol, 184, 2172-8. https://doi.org/10.1016/j.juro.2010.06.089
  6. Cho-Rok J, Yoo J, Jang YJ, et al (2006). Adenovirus-mediated transfer of siRNA against PTTG1 inhibits liver cancer cell growth in vitro and in vivo. Hepatology, 43, 1042-52. https://doi.org/10.1002/hep.21137
  7. Chung CS, Chen MH, Cullen J, et al (2008). Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality. Urology, 71, 136-40. https://doi.org/10.1016/j.urology.2007.08.028
  8. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR (2003). National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst, 95, 981-9. https://doi.org/10.1093/jnci/95.13.981
  9. El-Naggar SM, Malik MT, Kakar SS (2007). Small interfering RNA against PTTG: a novel therapy for ovarian cancer. Int J Oncol, 31, 137-43.
  10. Ghayad SE, Vendrell JA, Bieche I, et al (2009). Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer. J Mol Endocrinol, 42, 87-103.
  11. Hao XP, Willis JE, Pretlow TG, et al (2000). Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions. Cancer Res, 60, 18-21.
  12. Heaney AP, Horwitz GA, Wang Z, Singson R, Melmed S (1999). Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis. Nat Med, 5, 1317-21. https://doi.org/10.1038/15275
  13. Heaney AP, Singson R, McCabe CJ, et al (2000). Expression of pituitary-tumour transforming gene in colorectal tumours. Lancet, 355, 716-9. https://doi.org/10.1016/S0140-6736(99)10238-1
  14. Holmes Jr L, Chan W, Jiang Z, Du XL (2007). Effectiveness of androgen deprivation therapy in prolonging survival of older men treated for locoregional prostate cancer. Prostate Cancer Prostatic Dis, 10, 388-95. https://doi.org/10.1038/sj.pcan.4500973
  15. http://seer.cancer.gov/csr/1975_2007/results_single/sect_01_table.01.pdf
  16. Kakar SS, Malik MT (2006). Suppression of lung cancer with siRNA targeting PTTG. Int J Oncol, 29, 387-95.
  17. Kawakami J, Cowan JE, Elkin EP, et al (2006). Androgendeprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer, 106, 1708-14. https://doi.org/10.1002/cncr.21799
  18. Kim DS, Franklyn JA, Boelaert K, et al (2006). Pituitary tumor transforming gene (PTTG) stimulates thyroid cell proliferation via a vascular endothelial growth factor/kinase insert domain receptor/inhibitor of DNA binding-3 autocrine pathway. J Clin Endocrinol Metab, 91, 4603-11. https://doi.org/10.1210/jc.2006-1291
  19. Kwak C, Jeong SJ, Park MS, Lee E, Lee SE (2002). Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol, 168, 995-1000. https://doi.org/10.1016/S0022-5347(05)64559-4
  20. Labrie F, Candas B, Gomez JL, Cusan L (2002). Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? Urology, 60, 115-9.
  21. Liang M, Chen X, Liu W, et al (2011). Role of the pituitary tumor transforming gene 1 in the progression of hepatocellular carcinoma. Cancer Biol Ther, 11, 337-45. https://doi.org/10.4161/cbt.11.3.14102
  22. Malik MT, Kakar SS (2006). Regulation of angiogenesis and invasion by human Pituitary tumor transforming gene (PTTG) through increased expression and secretion of matrix metalloproteinase-2 (MMP-2). Mol Cancer, 5, 61-73. https://doi.org/10.1186/1476-4598-5-61
  23. Pei L, Melmed S (1997). Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol Endocrinol, 11, 433-41. https://doi.org/10.1210/me.11.4.433
  24. Ramaswamy S, Ross KN, Lander ES, Golub TR (2003). A molecular signature of metastasis in primary solid tumors. Nat Genet, 33, 49-54. https://doi.org/10.1038/ng1060
  25. Rehfeld N, Geddert H, Atamna A, et al (2006). The influence of the pituitary tumor transforming gene-1 (PTTG-1) on survival of patients with small cell lung cancer and non-small cell lung cancer. J Carcinog, 5, 4-12. https://doi.org/10.1186/1477-3163-5-4
  26. Sharma A, Comstock CE, Knudsen ES, et al (2007). Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Res, 67, 6192-203. https://doi.org/10.1158/0008-5472.CAN-06-4424
  27. Solbach C, Roller M, Eckerdt F, Peters S, Knecht R (2006). Pituitary tumor-transforming gene expression is a prognostic marker for tumor recurrence in squamous cell carcinoma of the head and neck. BMC Cancer, 6, 242-9. https://doi.org/10.1186/1471-2407-6-242
  28. Solbach C, Roller M, Fellbaum C, Nicoletti M, Kaufmann M (2004). PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence. Breast, 13, 80-1. https://doi.org/10.1016/j.breast.2003.09.008
  29. Vlotides G, Eigler T, Melmed S (2007). Pituitary tumor-transforming gene: physiology and implications for tumorigenesis. Endocr Rev, 28, 165-86. https://doi.org/10.1210/er.2006-0042
  30. Wuttig D, Baier B, Fuessel S, et al (2009). Gene signatures of pulmonary metastases of renal cell carcinoma reflect the disease-free interval and the number of metastases per patient. Int J Cancer, 125, 474-82. https://doi.org/10.1002/ijc.24353
  31. Zhang L, Yang BX, Zhang HT, et al (2011). Prostate cancer: an emerging threat to the health of aging men in Asia. Asian J Androl, 13, 574-8. https://doi.org/10.1038/aja.2010.126
  32. Zhang X, Horwitz GA, Prezant TR, et al (1999). Structure, expression, and function of human pituitary tumortransforming gene (PTTG). Mol Endocrinol, 13, 156-66. https://doi.org/10.1210/me.13.1.156
  33. Zhou C, Liu S, Zhou X, et al (2005). Overexpression of human pituitary tumor transforming gene (hPTTG), is regulated by beta-catenin/TCF pathway in human esophageal squamous cell carcinoma. Int J Cancer, 113, 891-8. https://doi.org/10.1002/ijc.20642
  34. Zhu X, Mao Z, Na Y, et al (2006). Significance of pituitary tumor transforming gene 1 (PTTG1) in prostate cancer. Anticancer Res, 26, 1253-9.
  35. Zou H, McGarry TJ, Bernal T, Kirschner MW (1999). Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science, 285, 418-22. https://doi.org/10.1126/science.285.5426.418

Cited by

  1. MiRNA-494 inhibits metastasis of cervical cancer through Pttg1 vol.36, pp.9, 2015, https://doi.org/10.1007/s13277-015-3440-0
  2. Interleukin-6/signal transducer and activator of transcription 3 promotes prostate cancer resistance to androgen deprivation therapy via regulating pituitary tumor transforming gene 1 expression vol.109, pp.3, 2018, https://doi.org/10.1111/cas.13493